Denali Therapeutics Inc. Selling, General and Administrative Expense
Denali Therapeutics Inc. (DNLI) reported Selling, General and Administrative Expense of $36.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Denali Therapeutics Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $36.28M, a 12.45% increase year-over-year.
- Denali Therapeutics Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $32.27M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month |
|---|---|---|
| 2026-06-30 | $36.28M 10-Q · filed 2026-08-06 | $69.79M 10-Q · filed 2026-08-06 |
| 2025-06-30 | $32.27M 10-Q · filed 2026-08-06 | $61.62M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |